A new agent for tumour necrosis factor-alpha inhibition

References

• Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998; 22:382–9.
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Targan SR. Tumor Necrosis Factor: Biology and Therapeutic Inhibitors. Gastroenterology. 2000; 119:1148–57.
   PubMed Web of Science ®Google Scholar
• Noji T, Karasawa A, Kusaka H. Adenosine uptake inhibitors. Eur J Pharmacology. 2004; 495:1–16.
   PubMed Web of Science ®Google Scholar
• Soop A, Johansson C, Hjemdahl P, Kristiansson M, Gyllenhammar H, Li N, Sollevi A. Adenosine treatment attenuates cytokine ınterleukin-6 responses to endotoxin challenge in healthy volunteers. Shock. 2003; 19:503–7.
   PubMedGoogle Scholar
• Cutolo M, Sulli A, Pizzorni C, Seriolo B. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001; 60:729–35.
   PubMed Web of Science ®Google Scholar
• Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost. 1986; 55:12–8.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE. Definition and diagnosis in regional enteritis. Skandia International Symposium Nordiska. Stockholm: SISN. 1971; :105–16.
   Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70:439–44.
   PubMed Web of Science ®Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of severity of Crohn's disease: a prospective multicentre study. Gut. 1989; 30:983–9.
   PubMed Web of Science ®Google Scholar
• Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ. A randomised doseresponse and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 1999; 13:1597–604.
   PubMed Web of Science ®Google Scholar
• Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabó C. Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 2000; 14:2065–74.
   PubMed Web of Science ®Google Scholar
• Noji T, Nan-ya K, Mizutani M, Katagiri C, Sano J, Takada C, Nishikawa S, Karasawa A, Kusaka H. KF24345, an adenosine uptake inhibitor, ameliorates the severity and mortality of lethal acute pancreatitis via endogenous adenosine in mice. Eur J Pharmacology. 2002; 454:85–93.
   PubMedGoogle Scholar
• Noji T, Sato H, Sano J, Nishikawa S, Kusaka H, Karasawa A. Treatment with an adenosine uptake inhibitor attenuates glomerulonephritis in mice. Eur J Pharmacology. 2002; 449:293–300.
   PubMedGoogle Scholar
• Gessi S, Varani K, Merighi S, Ongini E, Borea PA. A2A adenosine receptors in human peripheral blood cells. Br J Pharmacol. 2000; 129:2–11.
   PubMed Web of Science ®Google Scholar
• Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, Poindron P, Duclos B. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut. 1997; 40:475–80.
   PubMed Web of Science ®Google Scholar
• Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S. Endogenous adenosine curtails, lipopolysaccharidestimulated tumour necrosis factor synthesis. Scand J Immunol. 1997; 45:132–9.
   PubMed Web of Science ®Google Scholar
• Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002; 50:196–200.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004; 126:1593–610.
   PubMed Web of Science ®Google Scholar
• Massia M, Bianchi A, Attisano C, Dianzani U, Boccadoro M, Pileri A. Dipyridamole in vitro suppresses the generation of T-cell cytotoxic functions: synergistic activity with cyclosporine. Eur J Haematol. 1991; 46:6–10.
   PubMedGoogle Scholar
• Le Vraux V, Chen YL, Masson I, De Sousa M, Giroud JP, Florentin I, Chauvelot-Moachon L. Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sci. 1993; 52:1917–24.
   PubMed Web of Science ®Google Scholar
• Kasyapa CS, Ramanadham M. Alkalin phosphatase activity is expressed only in B lymphocytes committed to proliferation. Immunol Lett. 1992; 31:111–6.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Gangle A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000; 119:1781–3.
   PubMedGoogle Scholar
• Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000; 119:1461–72.
   PubMed Web of Science ®Google Scholar
• Le Moine O, Stordeur P, Schandene L, Marchant A, de Groote D, Goldman M, Devière J. Adenosine enhances IL-10 secretion by human monocytes. J Immunol. 1996; 156:4408–14.
   PubMed Web of Science ®Google Scholar
• Schmith A, Carol M, Robert F, Bontems P, Houben JJ, Van Gossum A, Goldman M, Mascart F. Dose-effect of interleukin-10 and its immunoregulatory role in Crohn's disease. Eur Cytokine Netw. 2002; 13:298–305.
   PubMedGoogle Scholar
• Detkova Z, Kupcova V, Prikazska M, Turecky L, Weissova S, Jahnova E. Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease. Physiol Res. 2003; 52:95–100.
   PubMedGoogle Scholar